Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/insilico-medicine-cayman-topco" target="_blank" data-smartkarma-citation="entities:39890:1" rel="noopener">InSilico Medicine Cayman TopCo (ISM HK)</a> shares rallied more than 200% since debut on HK stock exchange. The rally is backed by successive deals stuck with renowned pharmaceutical companies.</li>
<li>InSilico Medicine and China Medical System Holdings entered into a strategic partnership to advance a series of AI-empowered drug discovery collaborations across multiple projects in CNS and autoimmune diseases.</li>
<li>Insilico’s AI-driven platform validated by rapidly bringing multiple drug candidates to IND enabling and clinical stage and business development expertise leading to multiple out-licensing collaborations entail long-term growth prospect.</li>
</ul>



InSilico Medicine Cayman TopCo (ISM HK) shares rallied more than 200% since debut on HK stock exchange. The rally is backed by successive deals stuck with renowned pharmaceutical companies.
InSilico Medicine and China Medical System Holdings entered into a strategic partnership to advance a series of AI-empowered drug discovery collaborations across multiple projects in CNS and autoimmune diseases.
Insilico’s AI-driven platform validated by rapidly bringing multiple drug candidates to IND enabling and clinical stage and business development expertise leading to multiple out-licensing collaborations entail long-term growth prospect.


InSilico Medicine (ISM HK): Firing on Both Cylinders

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

<ul><li>Exelixis' second quarter 2025 financial results highlight both significant achievements and ongoing challenges for the biotechnology company.</li><li>Revenue growth and product development are key aspects to consider when forming an investment thesis.</li><li>In terms of financial performance, Exelixis reported total revenue of $568 million, with the cabozantinib franchise contributing $520 million.</li></ul>

Exelixis' second quarter 2025 financial results highlight both significant achievements and ongoing challenges for the biotechnology company.Revenue growth and product development are key aspects to consider when forming an investment thesis.In terms of financial performance, Exelixis reported total revenue of $568 million, with the cabozantinib franchise contributing $520 million.

Exelixis Inc.: The Advancement in Early Clinical Pipeline & Other Major Drivers!

<ul><li>Exelixis recently shared its financial results for the first quarter of 2025, which revealed a mix of promising developments and some areas that warrant caution.</li><li>The company demonstrated strong financial performance, reporting significant growth in its key product, cabozantinib, which generated $513 million in net product revenue in the U.S., marking a 36% increase year-over-year.</li><li>The global net product revenue for the cabozantinib franchise was approximately $680 million.</li></ul>

Exelixis recently shared its financial results for the first quarter of 2025, which revealed a mix of promising developments and some areas that warrant caution.The company demonstrated strong financial performance, reporting significant growth in its key product, cabozantinib, which generated $513 million in net product revenue in the U.S., marking a 36% increase year-over-year.The global net product revenue for the cabozantinib franchise was approximately $680 million.

Exelixis Inc.: Will It Be Able To Build On The XB628 & Other Pipeline Expansion Opportunities?

<ul><li>Exelixis reported a robust performance for the fourth quarter and fiscal year 2024, highlighting significant financial growth and ongoing developments in their oncology portfolio.</li><li>The company's total revenues for the fourth quarter reached approximately $567 million, driven by the strong performance of the cabozantinib franchise, specifically CABOMETYX, which achieved net product revenues of $515.2 million.</li><li>For the full year 2024, Exelixis reported U.S. cabo franchise net product revenues of $1.81 billion, reflecting substantial year-over-year growth.</li></ul>

Exelixis reported a robust performance for the fourth quarter and fiscal year 2024, highlighting significant financial growth and ongoing developments in their oncology portfolio.The company's total revenues for the fourth quarter reached approximately $567 million, driven by the strong performance of the cabozantinib franchise, specifically CABOMETYX, which achieved net product revenues of $515.2 million.For the full year 2024, Exelixis reported U.S. cabo franchise net product revenues of $1.81 billion, reflecting substantial year-over-year growth.

Exelixis Inc.: Pipeline Expansion & Innovation to Build A Robust Portfolio!

<ul><li>Exelixis Inc. reported its third quarter results for 2024, demonstrating a robust financial and commercial standing, underpinned by significant contributions from its flagship product, cabozantinib, as well as promising developments in its pipeline, particularly with zanzalintinib (zanza).</li><li>The company projects substantial growth opportunities, buoyed by strategic collaborations and new drug developments.</li><li>Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.</li></ul>

Exelixis Inc. reported its third quarter results for 2024, demonstrating a robust financial and commercial standing, underpinned by significant contributions from its flagship product, cabozantinib, as well as promising developments in its pipeline, particularly with zanzalintinib (zanza).The company projects substantial growth opportunities, buoyed by strategic collaborations and new drug developments.Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

Exelixis Inc.: These Are The 4 Biggest Challenges That Justify Our Lack Of Optimism! - Major Drivers

United States

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases.  The Company is building a portfolio of compounds it believes could become pharmaceutical products.  Exelixis has strategic alliances with pharmaceutical and biotechnology companies.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Exelixis Inc (EXEL US)

InSilico Medicine (ISM HK): Firing on Both Cylinders

Insilico Medicine announced that ISM4808, an AI-driven potential best-in-class oral drug candidate for CKD-related anemia previously out-licensed...

Tina Banerjee

Exelixis Inc.: The Advancement in Early Clinical Pipeline & Other Major Drivers!

Exelixis' second quarter 2025 financial results highlight both significant achievements and ongoing challenges for the biotechnology...

Baptista Research

Exelixis Inc.: Will It Be Able To Build On The XB628 & Other Pipeline Expansion Opportunities?

Exelixis recently shared its financial results for the first quarter of 2025, which revealed a mix of promising developments and some areas that...

Baptista Research

Exelixis Inc.: Pipeline Expansion & Innovation to Build A Robust Portfolio!

Exelixis reported a robust performance for the fourth quarter and fiscal year 2024, highlighting significant financial growth and ongoing...

Baptista Research

Exelixis Inc.: These Are The 4 Biggest Challenges That Justify Our Lack Of Optimism! - Major Drivers

Exelixis Inc. reported its third quarter results for 2024, demonstrating a robust financial and commercial standing, underpinned by significant...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)